New CKD Diagnostic Tools Could Transform Detection for 800 Million Patients

Chronic kidney disease is a global health crisis, silently affecting between 788 and 844 million adults worldwide. Despite its scale, CKD remains dramatically underdiagnosed, particularly in low- and middle-income countries where access to basic kidney function testing is limited. A comprehensive 2026 Lancet review synthesises the latest advances in CKD detection and diagnosis, providing both a state-of-the-field assessment and a roadmap for improvement.

The review highlights several key diagnostic innovations. Cystatin C is emerging as a superior alternative or complement to creatinine for estimating glomerular filtration rate, offering greater accuracy across diverse populations. Albuminuria—protein in the urine—is now firmly recognised as a critical screening marker and tool for risk stratification, identifying patients at elevated cardiovascular and renal risk earlier than GFR alone.

Beyond blood and urine markers, kidney biopsy techniques are improving diagnostic precision and prognostic capability. Multiomics approaches—integrating genomics, proteomics, and metabolomics—are deepening mechanistic understanding and opening pathways for precision nephrology. Artificial intelligence combined with advanced imaging is enabling non-invasive diagnosis and population-level case detection, potentially replacing or delaying the need for invasive procedures.

On the population level, screening programs using estimated GFR and albuminuria are increasingly cost-effective, especially given the expanding arsenal of CKD-modifying therapies such as SGLT2 inhibitors. Disease-specific risk prediction models are enhancing individualised clinical decision-making, supporting earlier intervention.

Despite these advances, the authors caution that inequitable global access, insufficient validation of tools across diverse ethnic populations, inconsistent biomarker standardisation, and fragile health system infrastructure in many regions limit real-world impact. The review calls for coordinated international investment in diagnostics, laboratory infrastructure, and workforce training to ensure these innovations benefit all patients, not just those in well-resourced settings.